Valuation: BioNTech SE

Market Cap 20.85B 23.75B 19.19B 17.89B 33.73B 2,258B 34.42B 231B 89.45B 1,108B 89.18B 87.25B 3,857B P/E 2026 *
-18.7x
P/E 2027 * -18.4x
Enterprise Value 10B 11.39B 9.21B 8.58B 16.18B 1,083B 16.51B 111B 42.9B 532B 42.77B 41.84B 1,850B EV / Sales 2026 *
4.62x
EV / Sales 2027 * 5.19x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+0.92%
1 week+4.11%
Current month+0.93%
1 month+2.42%
3 months+5.03%
6 months-1.34%
Current year-1.34%
1 week 88.82
Extreme 88.825
95.08
1 month 84.96
Extreme 84.955
95.08
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Director/Board Member 72 2021-12-31
Director/Board Member 69 2008-06-01
Director/Board Member 65 2026-05-14
Date Insider Type Main position Quantity % Market Cap.
05-11Free

General Counsel

22,655 0.0094%
05-11Free

Executive/Senior Manager

22,655 0.0094%
05-11Free

Chief Operating Officer

22,655 0.0094%
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%+4.11%-12.64%-12.98% 23.75B
+2.19%+3.68%+73.28%+132.00% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.36%+3.42%+9.61%+407.11% 23.19B
+3.64%+8.34%+39.81%-5.88% 18.14B
+1.97%+5.75%+40.43%-29.81% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.20%+13.33%+42.13% - 12.97B
-4.20%+0.91%+71.37%+122.68% 11.86B
Average +1.77%+6.34%+53.97%+137.88% 24.78B
Weighted average by Cap. +1.57%+6.33%+57.32%+131.71%

Financials

2026 *2027 *
Net sales 2.17B 2.47B 1.99B 1.86B 3.5B 235B 3.57B 23.98B 9.29B 115B 9.26B 9.06B 401B 2.23B 2.54B 2.05B 1.91B 3.61B 242B 3.68B 24.69B 9.57B 119B 9.54B 9.33B 413B
Net income -1.05B -1.2B -967M -901M -1.7B -114B -1.73B -11.63B -4.51B -55.85B -4.49B -4.4B -194B -1.17B -1.33B -1.07B -1B -1.89B -126B -1.92B -12.9B -5B -61.94B -4.98B -4.88B -216B
Net Debt -10.85B -12.36B -9.99B -9.31B -17.55B -1,175B -17.91B -120B -46.55B -577B -46.41B -45.41B -2,007B -9.28B -10.57B -8.54B -7.96B -15.01B -1,005B -15.32B -103B -39.81B -493B -39.69B -38.83B -1,717B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-07-01 US$93.92 +0.93% 545,569
26-06-30 US$93.05 -1.28% 561,327
26-06-29 US$94.26 +3.33% 935,865
26-06-26 US$91.22 +1.36% 873,629
26-06-25 US$90.00 -0.23% 712,727
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
82.46EUR
Average target price
106.75EUR
Spread / Average Target
+29.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock